NCT00911898View on ClinicalTrials.gov

A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Her2 Amplified Solid TumorsMetastatic Breast Cancer
Interventions
DRUG

MM-111

For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV

Trial Locations (4)

19111

Fox Chase Center, Philadelphia

46268

Indiana University (IUPUI), Indianapolis

78229

South Texas Accelerated Research Therapeutics, San Antonio

90033

University of Southern California Norris Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Merrimack Pharmaceuticals

INDUSTRY

NCT00911898 - A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers | Biotech Hunter | Biotech Hunter